Navigation Links
Neurocrine Biosciences Reports First Quarter 2013 Results
Date:5/2/2013

SAN DIEGO, May 2, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced its financial results for the quarter ended March 31, 2013.  For the first quarter of 2013, the Company reported net loss of $12.1 million, or $0.18 loss per share, compared to a net loss of $0.9 million, or $0.01 loss per share, for the same period in 2012. This $11.2 million change in operating results is primarily due to lower revenue recognized during 2013 under the Company's license agreements with AbbVie and Boehringer Ingelheim. The sponsored research and development segments of both of these agreements concluded, as scheduled, during 2012.

The Company's balance sheet at March 31, 2013 reflected total assets of $183.9 million, including cash, cash equivalents, investments and receivables of $176.9 million compared with balances at December 31, 2012 of $196.0 million and $188.3 million, respectively.  

"AbbVie has made great progress with elagolix. The initiation of this Phase IIb study in uterine fibroids is another significant milestone for this program," said Kevin Gorman , Ph.D., President and Chief Executive Officer of Neurocrine Biosciences. "Our VMAT2 program also continues to move forward in two Phase IIb tardive dyskinesia studies, with an End of Phase II FDA meeting anticipated later this year."

Revenues for the first quarter of 2013 were $0.7 million compared with $11.3 million for the same period last year. The entire $10.6 million reduction in revenue is due to the successful completion of the sponsored research and development segments of the Company's license agreements with both AbbVie and Boehringer Ingelheim during 2012, as scheduled.

Research and development expenses increased to $10.3 million during the first quarter of 2013 from $9.4 million during the same pe
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
2. Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
3. Neurocrine Biosciences To Present At The 25th Annual Roth Conference
4. Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
5. Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
6. Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
7. Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
8. Neurocrine Biosciences To Present At Deutsche Banks 2012 dbAccess BioFEST
9. Neurocrine Biosciences To Present At Lazard Capitalmarkets 9th Annual Healthcare Conference
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
11. Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... , Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... commitments from institutional investors to purchase an aggregate of ... an at-the-market registered direct offering, led by a dedicated ... definitive purchase agreements with these investors pursuant to which ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... 2010 Abbott Diabetes Care today announced that it ... million strips) of Precision Xtra®, Precision Xceed Pro®, MediSense® ... Strips in the United States and Puerto Rico. ... Precision Xtra, Precision Xceed Pro, MediSense Optium, Optium and ...
... 2010 Heska Corporation (Nasdaq: HSKA ) announces ... to Its Special Meeting of Stockholders on the WebWhen: , ... (click on the Special Meeting of Stockholders link on ... Internet -- Simply log on to the web at the ...
Cached Medicine Technology:Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 2Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 3Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 4Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 5Abbott Diabetes Care Announces Recall of Certain Lots of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico 6Webcast Alert: Heska Corporation's Special Meeting of Stockholders Webcast 2
(Date:4/22/2014)... are more likely to have a child who develops ... A recent study from researchers from the Drexel University ... in Sweden provides more insight into how the risk ... ages, and found that the risk of having a ... for older parents., In the study, published in the ...
(Date:4/22/2014)... Based on results of a clinical trial led ... and Drug Administration (FDA) approved a molecularly targeted ... that has progressed after standard chemotherapy has failed. ... was announced by the manufacturer, Lilly Oncology, of ... ramucirumab, it will be sold under the name ...
(Date:4/22/2014)... identify patients who are at highest risk for respiratory ... condition, suggest data from a large multi-center study published ... Affecting nearly 200,000 Americans a year, acute respiratory distress ... caused by a number of issues ranging from smoke ... develop ARDS after surgery. ARDS is difficult to treat ...
(Date:4/22/2014)... out of the University of Calgary,s Hotchkiss Brain Institute ... nerve cells as a means to restore connections after ... a key molecule that directly regulates nerve cell growth ... in the prestigious journal Nature Communications , with ... "We made the surprising discovery that a protein ...
(Date:4/21/2014)... ROCHESTER, Minn. Acute respiratory distress syndrome is ... Patients who develop the lung disorder postoperatively are ... and those who survive the syndrome may still ... A Mayo Clinic-led study is helping physicians better ... toward preventing this dangerous and costly surgical complication. ...
Breaking Medicine News(10 mins):Health News:Child's autism risk accelerates with mother's age over 30 2Health News:Child's autism risk accelerates with mother's age over 30 3Health News:FDA approves first targeted drug for advanced stomach cancer 2Health News:New tool helps doctors better predict, prevent deadly respiratory failure 2Health News:Scientists discover a new way to enhance nerve growth following injury 2Health News:Acute respiratory distress syndrome: Study IDs surgical patients at risk 2
... that Snake Bites are Becoming More Powerful and Patient Reactions ... marks a change in rattlesnake behavior as well. Snakes ... the rattlesnake is. In humans, a rattlesnake bite can ... the past couple of years we have seen an increase ...
... 5 Argus Health Systems, Inc., a leading provider ... Topor has been elected to the National Council for ... three-year term. The Board of Trustees oversees all Council ... development activities. Prior to the election, Topor, a 12-year ...
... support the use of lower cost sharing as an incentive ... in order to reduce costs, according to survey data published ... have been interested in bringing aspects of "consumerism" into health ... 2009 EBRI Notes , which reports the survey data. ...
... aggressive goals to expand nationwide, Wellspring ... Development. Bill will spearhead the newly formed Network Development Division ... in 2010. He is responsible for making Wellspring a household ... former Fortune 100 senior executive with healthcare, insurance and leading ...
... revenues grow by 31% and gross profit increases 85%ROCHESTER, N.Y., ... a leading provider of quantitative imaging for clinical trials, announced ... over $2.1 million, a 31% increase over prior year,s first ... was $1,119,786 compared to $604,119 in the first quarter of ...
... Advisory Board Will Host ,Day of Dialogue, Online Town Hall ... 5, 2009 America,s healthcare and long-term services need to ... of today,s seniors and people with disabilities, according to a ... The report, which will be supported by a nationwide ...
Cached Medicine News:Health News:As the Weather Warms Up Rattlesnakes Come Out to Enjoy the Sun Just as Californians Do 2Health News:New Research from EBRI: Many Support Lower Cost Sharing to Change Health Care System Use 2Health News:Wellspring Hires William Young and Prepares for Nationwide Expansion 2Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 2Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 3Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 4Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 5Health News:VirtualScopics Reports Record Revenues and Gross Profit in the First Quarter 6Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 2Health News:National Advisory Board Issues 'Declaration for Independence': A Call-to-Action in Healthcare for Seniors and People with Disabilities 3
PremierEdge Stab Knives - 15....
DCR Set, Straight....
... CORNEO-GAGE PLUS pachometers are acknowledged to be ... measurement-reproducible pachometers available. These benefits are due ... transducers and smallest tip footprint available coupled ... average for every displayed reading. Thus corneal ...
... Leica CM1850 cryostat for standard ... laboratory is designed for easy ... A new insulation technology used, ... refrigerating system and maintains stable ...
Medicine Products: